Raymond James Resumes Coverage of Jazz Pharmaceuticals (JAZZ) With an Outperform Rating

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most undervalued biotech stocks to buy right now. On April 10, Raymond James resumed coverage of Jazz Pharmaceuticals (NASDAQ:JAZZ) with an Outperform rating and set a price target of $227. The firm told investors that the Jazz story has travelled beyond the narrative of “it looks inexpensive/fairly valued, but where can I get upside?” since adding greater visibility to the tail value of the Epidiolex franchise and zanidatamab delivering “highly competitive” data in gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals plc (JAZZ): Among Billionaire Ray Dalio’s Bridgewater’s Stock Picks with Huge Upside Potential

Jazz Pharmaceuticals (NASDAQ:JAZZ) also received a rating update from Piper Sandler on March 19, with the firm lifting the price target on the stock to $232 from $219 while maintaining an Overweight rating on the shares. The firm stated that moving further into 2026, it continues to view the company as undervalued at a current EV/2026E EBITDA of only seven times in the context of a company that has strong visibility into double-digit overall top-line growth starting in 2027. Piper added that the competitive dynamics associated with the oxybate franchise are not lost on it, but it does not envision said dynamics throwing a wrench into its thinking regarding Jazz Pharmaceuticals’ (NASDAQ:JAZZ) overall growth profile.

Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection. These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.

While we acknowledge the risk and potential of JAZZ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JAZZ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.